AĞIZ İÇİ NEMLENDİRİCİ ÖZELLERİ OLAN İKİ JELİN

Öz

-

Anahtar Kelimeler

• -

AĞIZ İÇİ NEMLENDİRİCİ ÖZELLERİ OLAN İKİ JELİN

Öz

Çal% mada a6%z içi nemlendirici özelli6i olan iki farkl% jelin viskozite özelliklerinin belirlenmesi ve do6al tükürükle kar %la t%r%lmas% amaçlanm% t%r.Jellerin ve do6al tükürü6ün viskozite ölçümleri Brookfield dijital viskozimetre cihaz% (Model DV-III) kullan%larak oda s%cakl%6%nda ve vücut %s%s%nda (37ºC’ de) gerçekle tirilmi tir. Sa6l%kl% 5 ki iden toplanan tükürük örneklerinin viskozite ölçümleri de yapay tükürük preparatlar%yla ayn% artlarda gerçekle tirilmive her bir örnekten 10 ölçüm yap%larak ortalama viskozite de6erleri elde edilmi tir. Oda s%cakl%6%nda yap%lan ölçümlerde jellerin viskozite özelliklerinin birbirine benzedi6i, ancak 37ºC’de BioXtra®’n%n istatistiksel olarak daha dü ük viskoziteye sahip oldu6u gözlenmi tir (p

Anahtar Kelimeler

• tükürük, viskozite, was similar to that of natural saliva

Kaynakça

1. Pederson AM, Bardow A, Jensen SB, Nauntofte B. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Diseases 2002; 8:117-129.
2. Chiappin S, Antonelli G, Gatti R, De Palo EF. Saliva specimen: A new laboratory tool for diagnostic and basic investigation. Clinica Chimica Acta 2007; 383:30-40.
3. Atkinson JC, Grisius M, Massey W. Salivary hypofunction and xerostomia:Diagnosis and treatment. Dent Clin N Am 2005; 49:309-326.
4. Christersson CE, Lindh L, Arnebrant T. Filmforming properties and viscosities of saliva substitutes and human whole saliva. Eur J Oral Sciences 2000; 108: 418-425.
5. Narhi TO, Meurman JH, Ainamo A. Xerostomia and Hyposalivation. Drugs and Aging 1999; 15:103-116.
6. Puy CL. The role of saliva in maintaining oral health and as an aid to diagnosis. Med Oral Patol Oral Cir Bucal 2006; 11:449-455.
7. Ship JA. Diagnosing, managing, and preventing salivary gland disorders. Oral Diseases Tsifetaki N, Kitsos G, Paschides CA, Alamanos Y, Eftaxias V, Voulgari PV, Psilas K, Drosos AA. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome . Randomised 12 week controlled study. Annals of the Rheumatic diseases 2003; 62:1204-1207.
8. Helenius LMJ, Meurman JH, Helenius I, Kar% K, Hietanen aj, Suuronen R, Hallikainen D, Kautianen H, Leirisalo-Repo M, Lindqvist C. Oral and salivary parameters in patients with rheumatic diseases.Acta Odontol Scand 2005; 63: 284-293.

9. Alpöz E, Güneri P, Önder G, Çankaya H, Kabasakal Y, Kose T. The efficacy of Xialine((R)) in patients with Sjögren's syndrome: a singleblind, cross-over study. Clin Oral Investig. 2008; 12: 165-72.
10. Samarawickrama DYD. Saliva substitutes: how effective and safe are they? Oral Diseases 2002: 8; 177-179.
11. Tenovuo J. Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia and safety. Oral Diseases 2002; 8: 23-29.
12. Kelly HM, Deasy PB, Busquet M, Torrance AA. Bioadhesive, rheological, lubricant and otheaspects of an oral gel formulation intended fort he treatment of xerostomia. Int J Pharm 2004: 278; 391-406.
13. Bergdahl M. Salivary flow and oral complaints in adult patients. Community Dent Oral Epidemiol 2000; 28: 59-66.
14. Alves MB, Motta CF, Messina MS, Migliari DA. Saliva substitute in xerostomic patients with primary Sjögren’s syndrome:A single-blind trial. Quintessence Int 2004; 35: 392-396.
15. Khurshudian AV. Apilot study to test the efficacy of oral administration of interferon lozenges to patients with Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 38-44.
16. Soto-Rojas A, Kraus A. The Oral Side of SjögrenSyndrome. Diagnosis and Treatment. A Review. Arch Med Research 2002; 33:95-106.
17. Dirix P, Nuyts S, Van den Bogaert W. Radiationinduced xerostomiain patients with head and neck cancer. Cancer 2006; 107: 25-34.
18. Cassolato SF, Turnbull RS. Xerostomia: Clinical Aspects and treatment. 2003; 20:64-77
19. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97:28-46.
20. Park MS, Chung JW, Kim YK, Chung SC, Kho HS. Viscosity and wettability of animal mucin solutions and human saliva. Oral Dis 2007; 13:181-6.
21. Scully CBE. Drug effects on salivary glands:dry mouth. Oral Diseases 2003; 9:165-176.
22. Johansson G, Andersson G, Edwardsson S, Björn A-Lisa, Manthorpe R, Attsröm R. Effects of muthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren syndrome. A double-blind crossover investigation. Gerodontology 2001; 18:87-94.
23. Kirstila V, Lenander-Lumikari M, Soderling E, Tenovuo. Effects of oral hygiene products containing lactoperoxidase, lysozyme, and lactoferrin on the composition of whole saliva and on subjective oral symptoms in patients with xerostomia. Acta Odontol Scand 1996; 54:391397.
24. Jellama AP, Langendijk H, Bergenhenegouwen L, Van der Reijden, Leemans R, Smeele L, Slotman BJ. The efficiacy of Xialine in patients with xerostomia resulting from radiotheraphy for head and head neck cancer:a pilot-study. Radiotheraphy and Oncology 2001; 59:157-160.
25. Smith G, Smith AJ, Shaw L, Shaw MJ. Artificial saliva substitutes and mimeral dissolution. J Oral Rehab 2001; 28: 728-731.
26. Preetha A, Banerjee R. Comparison of Artificial Saliva Substitutes. Trends Biomater Aktif Organs 2005; 18:178-186.
27. Zussman E, Yarin AL, Nagler RM. Age and flow dependency of salivary viscoelasticity. J Dent Res 2007; 86:281.
28. Jorkjend L, Johansson A, Johansson AK, Bergenholtz. Resting and stimulated whole salivary flow rates in Sjögren’s syndrome patients over time:a diagnostic aid for subdized dental care? Acta Odontol Scand 2004; 62: 264-268
29. Vissink A, Waterman HA, Gravenmade EJ, Panders AK, Vermey A. Rheological properties of saliva substitutes containing mucin, carboxymethylcellulose or polyethylenoxide. J Oral Pathol Med 1984; 13:22-28.
30. Shahdad SA. A double-blind, cross-over study of Biotene Oralbalance and Bioxtra systems as salivary substitutes in patients with postradiotheraphy xerostomia. European Journal of Cancer Care 2005; 14:319-326.
31. Hatton MN, Levine MJ, Margarone JE, Aguirre A. Lubrication and viscosity features of human saliva and commercially available saliva substitutes. J Oral Maxillofac Surg. 1987; 45: 496-9.
32. Mellema J, Holterman HJ, Waterman HA, Blom C, Gravenmade EJ. Rheological aspects of mucincontaining solutions and saliva substitutes. Biorheology 1992; 29:231-49.
33. Fox PC. Salivary Enhancement Therapies. Caries Res 2004; 38: 241-246.
34. Urquhart D, Fowler CE. Review of the use of polymers in saliva substitutes for symptomatic relief of xerostomia. J Clin Dent 2006; 17: 29-33.